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PCARDIOVASCULAR GENOMIC MEDICINE
Atherosclerosis
The Path From Genomics to Therapeutics
David T. Miller, MD, PHD,*§ Paul M Ridker, MD, MPH, FACC,†‡§ Peter Libby, MD, FACC,‡§
David J. Kwiatkowski, MD, PHD*§
Boston, Massachusetts
Recent rapid advances in genomic tools and techniques hold great promise for transforming the practice of car-
diovascular medicine. Resources including the Human Genome Project and the International HapMap project,
major technological advances in high-throughput genotyping and methods of statistical analysis, and methods
for high-throughput gene expression and small molecule profiling allow researchers to confront issues that will
fundamentally change the practice of cardiovascular medicine during the 21st century. Genomic, proteomic, and
metabolomic studies of complex cardiovascular diseases such as atherosclerosis will bridge epidemiology and
basic biology, and promise increased understanding of cardiovascular disease processes. Genetic approaches
applied to atherosclerosis will continue to identify genes and pathways involved in the predisposition to and
pathophysiology of atherosclerosis. Gene expression profiling refines our understanding of the dynamic na-
ture of the atherosclerotic vascular wall and promises discovery and validation of targets for therapeutic
intervention. Opportunities to translate genetic, genomic, proteomic, and metabolomic information into car-
diovascular clinical practice have never been greater, but their fruition requires validation in large indepen-
dent cohorts, achieved only through collaborative effort. Their continued success will depend on ongoing
cooperation within the cardiovascular research community. (J Am Coll Cardiol 2007;49:1589–99)
© 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.12.045c
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ghis state-of-the-art review focuses on research that applies
ajor technological developments in genomic medicine to
therosclerotic cardiovascular disease. High-throughput
echnologies facilitate identification of genetic, genomic,
roteomic, and metabolomic markers of coronary artery
isease (CAD) risk that may find a place in clinically useful
rediction algorithms. Such risk models would augment the
tility of established clinical tools such as the Framingham
isk score. However, putative genomic, proteomic, and
etabolomic markers will require the same rigor in appli-
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ccepted December 4, 2006.ation as other epidemiologic markers. Ultimately, the
ranslation of such information to clinical practice should
nhance “personalized medicine.” The coupling of informa-
ion gained through genomic, proteomic, and metabolomic
ethodologies to traditional tools should sharpen our ability
o assess and modify management of cardiovascular disease.
Despite steady progress, atherosclerotic cardiovascular
isease remains a growing public health burden in devel-
ped countries, and advances in cardiovascular research will
ot realize their full impact unless translated to care of
ndividual patients (1). Hope for determining new thera-
eutic targets in atherosclerosis increasingly rests on re-
earch progress in genetic studies, expression profiling, and
roteomics (2–7). Combining new markers of cardiovascu-
ar disease with currently available screening tools promises
o promote this translational process.
Before a personalized medicine approach to atheroscle-
osis based on genomics, proteomics, and metabolomics can
ecome reality, researchers must validate novel markers
cross different cohorts and in relation to various environ-
ental modifiers. The operation of intricate networks of
enes, environmental factors, and gene-by-environment
nteractions further complicates our understanding of the
enetic components of atherosclerosis (8,9). Combined
enomic approaches, often called genomic convergence, are
ecessary in atherosclerosis research (7).
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genetics and genomics have facil-
itated 2 major approaches to un-
derstanding disease pathogenesis
and risk. First, the Human Ge-
nome Project and International
HapMap Project now allow us to
obtain with relative speed vast
amounts of deoxyribonucleic acid
(DNA)-based information appli-
cable to research subjects with
atherosclerotic cardiovascular
disease. Second, current technol-
ogy enables collection of infor-
mation on expression for thou-
sands of genes in vascular cells
and tissues under different con-
ditions. The human DNA se-
quence laid the groundwork for
studies of genetic susceptibility to
disease, and expression databases
assist definition of disease subtypes
and variance related to environ-
mental interactions. Although
currently less mature technolo-
gies, proteomic and metabolomic
studies promise to complement
genomic approaches. Table 1
compares advantages and disad-
vantages of methods for marker
identification.
A patient-specific risk profile
for cardiovascular disease gener-
ated by knowledge of the genetic
nderpinnings of human disease risk would likely assist the
linician in providing targeted interventions, e.g., drugs that
ct on only a subset of the population or avoiding a
articular environmental exposure known to interact with a
enetic variant. Both examples illustrate personalized med-
cine. Although current technology enables researchers to
mass huge amounts of genomic data in a relatively short
ime frame, translation to the clinic will require demon-
trated effects on outcomes. Indeed, the bottleneck for
ranslation of genomic medicine to everyday practice lies at
hat intersection of knowledge.
enetic Studies of
therosclerotic Cardiovascular Disease
enetic linkage studies. Using families and anonymous
NA markers, genetic linkage studies correlate inherited
enomic regions with inherited familial characteristics. Al-
hough the many genes and environmental factors influenc-
ng atherosclerosis make direct linkage difficult, numerous
xamples link phenotypes with atherosclerotic cardiovascu-
Abbreviations
and Acronyms
ALOX5AP  5-lipoxygenase
activating protein gene
CAD  coronary artery
disease
CRP  C-reactive protein
FLAP  5-lipoxygenase
activating protein
HMG-CoA  5-hydroxy-3-
methylglutaryl-coenzyme A
HSP27  heat shock
protein-27
LDL  low-density
lipoprotein
LTA4H  leukotriene A4
hydrolase gene
LTB4  leukotriene B4
MI  myocardial infarction
MMP  matrix
metalloproteinase
OR  odds ratio
Osm  oncostatin M
Osmr  oncostatin M
receptor
PCSK9  proprotein
convertase subtilisin/kexin
type 9 serine protease
SNP  single nucleotide
polymorphism
TNFSF4  tumor necrosis
factor (ligand) superfamily,
member 4ar disease. The work of Goldstein and Brown (10) on aow-density lipoprotein (LDL)-receptor mutations in fa-
ilial hypercholesterolemia furnished a foundation for
nderstanding the mechanism of LDL lowering by
-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) re-
uctase inhibitors. However, single-gene defects in lipid
etabolic pathways account only for a very small portion of
amilial and sporadic atherosclerosis (11). In most people,
ultiple genes and environmental factors determine ele-
ated lipid levels and atherosclerotic events. Among families
n which a single gene plays a stronger role, evidence of
inkage frequently identifies a chromosomal locus but not
ingle genes for atherosclerotic cardiovascular disease
12–16).
Notably, linkage analysis has successfully identified spe-
ific genes that may contribute to cardiovascular event risk,
or example, myocyte enhancer factor-2 (MEF2A) with
yocardial infarction (MI) risk (3) and arachidonate
-lipoxygenase activating protein gene (ALOX5AP) with
I and stroke risk (17). Helgadottir et al. (17) showed
inkage between the ALOX5AP gene region and MI in 296
celandic families, including 713 subjects. The ALOX5AP
ene encodes the enzyme 5-lipoxygenase activating protein
FLAP), which participates in leukotriene synthesis. Such
eukotrienes, especially leukotriene B4 (LTB4), mediate
nflammation within the vasculature and participate in
urine atherosclerosis (18). Helgadottir et al. (17) followed
p their suspicions about ALOX5AP with a genetic associ-
tion study approach (see the following text).
Human families with CAD are not the only resource for
inkage analysis. Almost 2 decades ago, linkage analysis
mong inbred mouse strains identified an atherosclerosis
usceptibility region on mouse chromosome 1 (Ath1). This
egion contains the tumor necrosis factor (ligand) superfam-
ly member 4 (Tnfsf4) gene, also termed Ox40l (19).
therogenic in mice, OX40L stimulates T cells. Other
uman studies recently linked the TNFSF4 region and the
egion containing the gene for OX40 (i.e., the OX40L
eceptor) to CAD (16,20), but did not identify the under-
ying gene in either case. Comparison of mouse and human
enetics ultimately led to TNFSF4, and further studies
howed an association between a TNFSF4 single nucleotide
olymorphism (SNP) and MI risk in women from 2 human
ohorts (19). Most recently, another study associated an
X40 SNP with MI risk (21), suggesting that this ligand-
eceptor interaction may provide a therapeutic target.
enetic association studies. Many genetic and environ-
ental factors likely influence complex diseases such as
therosclerosis. Viewed separately, each factor exerts a
elatively small effect. Combined, they might explain in-
reased disease risk. Compared with linkage studies, genetic
ssociation studies provide greater statistical power and
ore detailed knowledge of a genetic region, enhancing our
ttempt to understand the genetics of complex diseases such
s atherosclerosis. In general, these studies seek to identify
ifferences in the inheritance of particular SNP alleles
mong subjects with a differing clinical phenotype, such as
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April 17, 2007:1589–99 Atherosclerosis: Genomics to TherapeuticsI (cases vs. control subjects) or differing levels of a
iomarker such as C-reactive protein (CRP) or cholesterol
high vs. low levels).
andidate gene association studies. Association studies
ay take a candidate gene or genome-wide approach. Such
tudies often base selection of candidate genes on assump-
ions about biologically relevant genes. Thus, candidate
ene studies are biased against identification of novel genes.
or example, several groups including our own published
andidate gene association studies on the relationship be-
ween SNPs in the CRP gene and CRP levels based on
umerous prospective studies showing the influence of
aseline CRP levels on cardiovascular risk (22,23). Three
tudies in particular provide comprehensive coverage of all
ommon CRP SNPs (24–26). Figure 1 shows 7 common
RP SNPs (Fig. 1A), illustrating the sequence difference at
n SNP within exon 2 (Fig. 1B) and the generation of 6
ommon haplotypes that result when SNP alleles combine
Fig. 1C).
The SNPs associated with an intermediate phenotype are
ot always associated with the disease state itself. The third
RP SNP in Figure 1, rs3091244, consistently associates
ith higher CRP levels in multiple studies (24–27). Despite
hese consistent associations, the proportion of variance in
RP levels explained by CRP genotypes is only2%. These
NPs thus have only a modest influence on plasma CRP
evels. Family studies indicate that there must be additional
enetic factors contributing to CRP levels. To date, candi-
omparison of Genetic, Genomic, Proteomic, and Metabolomic Res
Table 1 Comparison of Genetic, Genomic, Proteomic, and Meta
Method Advantages
Genetic linkage study Identifies single genes with larg
Surveys the entire genome
Genetic association study More statistical power for comp
compared with linkage analy
Could be family-based or unrela
Finer resolution than linkage an
Candidate gene (100–1,000 SNPs) Lower cost than genome-wide s
Customized choice of SNPs
Whole genome (100,000–500,000 SNPs) Surveys entire genome, nothing
Huge amount of information pe
Identifies variants with relatively
Gene expression study Information at the tissue level
Real-time information about pa
changes
Customized chips for panels of
a process (e.g., inflammation
Proteomic/metabolomic study Information at the tissue level
Information about protein levels
genotype or mRNA levels
NP  single nucleotide polymorphism.ate gene SNP selection has achieved limited success in rnding genetic variants of CRP level, an example of the
forementioned bias against novel gene identification. Case-
ontrol studies to date have not been adequately powered to
valuate whether or not these SNPs impact on incident
isease (25,26,28).
Testing greater numbers of SNPs can increase the
hances of finding a disease-causing variant. Technological
dvances that reduce genotyping costs now allow researchers
o “supersize” their candidate gene studies. A recent study
ocused on 11,053 SNPs located within genes, reasoning
hat those SNPs more likely would affect gene function or
xpression (29). Using a case-control design and 3 rounds of
eplication, Shiffman et al. (29) identified 4 SNPs associated
ith risk of MI (all odds ratios [ORs] indicate carriers of 2
s. 0 risk alleles): the cytoskeletal protein paladin
KIAA0992 [OR 1.40]), a tyrosine kinase (ROS1 [OR
.75]), and 2 G-protein coupled receptors (TAS2R50 [OR
.58] and OR13G1 [OR 1.40]). Although these SNPs
epresent risks on par with accepted risk markers such as
ypertension and CRP (23), other attempts at replication
or this panel of SNPs yielded mixed results with as few as
in 5 SNPs having a similar magnitude and direction of
ffect (30). The determination of the generalizability of
enetic associations observed in a given study population
equires replication in independent samples, as discussed in
etail elsewhere (31).
Combining different genetic methodologies facilitates
iscovery. For example, genetic association studies help
h Methods
mic Research Methods
Disadvantages
t Limited power for complex diseases
Low resolution; must be followed by fine mapping and/or
candidate gene studies
Must be family-based; family may be affected by a rare gene
that has little influence among the general population
eases
bjects
Requires additional samples/cohorts for replication
Need large number of subjects (2,000 cases  2,000 controls)
to detect genetic markers with small effect
Only find associations in the genes chosen for analysis
d
l effect
Expensive because of SNP volume
Bioinformatics challenge
May miss a region of interest because of poor coverage
Requires multiple rounds of replication
siological
related to
Source tissue (e.g., biopsy) often poor quality or difficult to
obtain, resulting in small sample sizes
Variability between assays/samples because of experimental
and pathophysiological variation
Possible bias in types of genes discovered based on which chip
is selected
mRNA levels and protein levels not perfectly correlated
dless of
Post-translational processing leads to variability
Need source tissue (e.g., vascular biopsy)
Variability between assays/samples because of experimental
and pathophysiological variation (e.g., variability in sample
processing)
Not as amenable (yet) to high-throughput formatearc
bolo
e effec
lex dis
sis
ted su
alysis
tudy
misse
r assay
smal
thophy
genes
)
regarefine regions identified by linkage studies. After identifying
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Atherosclerosis: Genomics to Therapeutics April 17, 2007:1589–99inkage between MI and the region containing ALOX5AP,
elgadottir et al. (17) focused more closely on ALOX5AP,
s a candidate gene, sequencing the entire gene in 93
ffected individuals and 93 control subjects to identify a
anel of 48 common SNPs in ALOX5AP. A case-control
ssociation study genotyped these 48 ALOX5AP SNPs to
etermine differences in the inheritance of a particular
attern of SNPs, or haplotype, between subjects with MI (n
779) and control subjects (n 624). An inherited 4-SNP
aplotype, HapA, conferred an increased risk (nearly
-fold) for MI and stroke (relative risk 1.8, adjusted p 
.005). The LTB4 production in stimulated neutrophils
ncreased substantially in individuals with MI compared
ith control subjects, especially in male carriers of
LOX5AP HapA, who showed significantly greater LTB4
roduction compared with control subjects (p  0.0042).
ale carriers of the at-risk haplotype had the strongest
ssociation with disease and also had significantly greater
roduction of leukotriene-B4 (LTB4). The HapA also
ncreased risk of stroke (relative risk 1.67, p  0.000095).
o date, an association between ALOX5AP and stroke was
bserved in more than 1 cohort (32,33), but replication
Figure 1 Genetic Information: SNPs and Haplotypes
The C-reactive protein (CRP ) gene structure, single nucleotide polymorphisms
(SNPs), and haplotypes; (A) CRP consists of 2 exons comprising coding
regions (darkest shading) and noncoding regions (medium shading) and has 7
common SNPs indicated by rs numbers and relative position. (B) Sequencing
traces of a G/C SNP in exon 2 shows the G/G version (black peak, top) and
G/C version (black/blue peak, bottom). (C) Different combinations of alleles
at each of the 7 SNP positions create 6 common haplotypes for this set of
CRP SNPs. Illustration by Rob Flewell.tudies for ALOX5AP have provided mixed results (34). pMost recently, Helgadottir et al. (35) used additional
andidate gene association studies to expand the ALOX5AP
tory (35). Using a pathway approach, they studied the
eukotriene A4 hydrolase (LTA4H) gene, the enzyme re-
ponsible for the production of LTB4. They performed
NA sequencing of the LTA4H gene region (42 kb) in 93
ubjects with MI to identify 8 novel SNPs. Considered as
ingle markers, none of those 8 SNPs was significantly
ssociated with MI in further studies. Considering groups of
NPs as haplotype blocks revealed a particular haplotype,
alled HapK, significantly associated with MI. Each inher-
ted copy of HapK conferred a relative risk of 1.45 (p 
.035 after adjusting for the number of haplotypes tested).
Replication of genetic associations among subjects of
arious ethnicities addresses variability in SNP allele inher-
tance patterns among ethnic groups that could influence
he way a particular variant affects disease risk. As one
xample, Helgadottir et al. (35) studied LTA4H in 3
ndependent MI cohorts of European-Americans and
frican Americans from the U.S. The HapK was signifi-
antly associated with MI among the European-American
ubset of this cohort (relative risk 1.19; p  0.006), and also
onferred higher relative risk among the African-American
ubset (relative risk 3.57; p  0.000022). Presumably,
nderlying genetic and environmental differences between
he European-American and African-American subsets ex-
lain the difference in LTA4H-associated MI risk, under-
coring the need to include different ethnic populations in
enetic association studies (36). Rare variants in one popu-
ation may be relatively common in another, for example,
roprotein convertase subtilisin/kexin type 9 serine protease
PCSK9), where 2 nonsense mutations not present in
aucasians confer lower levels of LDL cholesterol and
rotection from CAD to African Americans (37).
Other efforts to determine genetic associations with
therosclerosis have achieved limited success in explaining a
ignificant proportion of the population-attributable risk
38,39), including several associations summarized else-
here (3,40). This inherent problem, not limited to the study
f cardiovascular disease, occurs in all genetic association
tudies of complex disease in which many genetic markers
ndividually explain only a fraction of the genetic contribution
o disease. Moreover, results from a genetic association study
equire replication through independent studies, as dis-
ussed in detail elsewhere (41).
enome-wide association studies. As the per-SNP costs
f high-throughput genotyping decline, cardiovascular re-
earchers are turning to genetic association studies on an
ven larger scale. In large prospective cohorts, so-called
enome-wide association studies examine hundreds of
housands of SNPs throughout the genome. Such studies,
ot hypothesis-driven, are suited ideally to discovering
reviously unimagined pathways for particular diseases.
The most significant disadvantage of genome-wide asso-
iation studies involves the statistical conundrum of multi-
le comparisons inherent in simultaneously performing
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April 17, 2007:1589–99 Atherosclerosis: Genomics to Therapeuticsssociation tests on thousands of markers. A study of
00,000 SNPs with a false-positive rate of 0.1% would
enerate 500 false-positive results, a very large number that
ecessitates multiple rounds of replication to confirm an
ssociation. Thus, thoroughly replicated results from
enome-wide association studies applied to cardiovascular
isease and related phenotypes have just now begun to
ppear (42).
ene Expression Profiling
n Cardiovascular Disease
alidating new discoveries related to atherosclerosis will
equire multiple complementary approaches (Fig. 2), in-
luding gene expression profiling. The SNP association
tudies cannot determine which SNPs may affect gene
xpression or function. Gene expression microarray tech-
ology, reviewed elsewhere (43), provides a way to scan
apidly specific tissues for patterns of expression among
Figure 2 Levels of Genomic and Proteomic Information
Capturing all genomic and proteomic information requires a combined
approach that targets DNA, RNA, and proteins. The single nucleotide polymor-
phisms (SNPs) may influence gene expression (e.g., by altering a transcrip-
tional activator binding site in the promoter), or gene function (e.g., by causing
an amino acid change). Transcriptional activators (TA), repressors (TR), and
mRNA turnover influence mRNA levels independent of SNP genotypes; these
mechanisms would only be detectable by expression profiling. Although mRNA
levels may vary within and among cells, regulation of protein trafficking, turn-
over, or structure could affect a protein level or function independently from
genotype or mRNA regulation. Illustration by Rob Flewell.housands of genes across the genome. Several studies in Hoth human and animal models have applied expression
rofiling technology to atherosclerosis. The general ap-
roach is exemplified by studies such as that by Ma and
iew (44), which used transcriptional profiling of peripheral
lood leukocytes among subjects with coronary heart disease
80% to 90% stenosis) versus healthy control subjects to
dentify 108 differentially expressed genes.
Although SNPs represent static information (the ge-
ome), expression profiles are dynamic (the transcriptome)
nd may show physiological fluctuations (Fig. 2). Expres-
ion profiling of atheromata in human aortic tissue collected
rom 63 heart donors indicated significant differences in
ene expression patterns for 212 genes, based on disease
everity and lesion location within the thoracic aorta (45).
mportantly, the investigators verified transcriptome reli-
bility and accuracy by comparing results obtained by more
raditional histological methods. Indeed, expression profil-
ng correctly classified disease severity and location in 93%
f samples tested.
Extending those findings, Karra et al. (46) recently reported
tudies of gene expression during atherosclerotic lesion pro-
ression. These studies compared a histologically determined
isease state with patterns of gene expression in mouse aortic
issue from wild-type and apolipoprotein E/ C57BL6/J
ice exposed to different diets and at different ages. Gene
xpression patterns varied according to disease stage: no disease
o early disease (197 genes, including many involved in lipid
etabolism), early to intermediate disease (146 genes, includ-
ng many involved in inflammation), intermediate to moderate
isease (110 genes), and moderate to severe disease (650
enes).
Importantly, Karra et al. (46) and Tabibiazar et al. (47)
rovide additional validation to these gene expression pat-
erns by showing consistent cross-species pattern compari-
ons. Referring the results of their mouse experiments to
arlier results in humans (45), Karra et al. (46) identified 40
enes among 650 (p  0.0001) that significantly correlated
ith disease progression in both mice and humans. Analyses
ased on the Gene Ontology database, a bioinformatics tool
esigned to facilitate clustering of genes based on functional
athways (48), bolstered the concordance between mice and
umans in both studies.
Overlapping genes identified in the 2 studies may provide a
eliable molecular signature for atherosclerotic disease states
Table 2). Many overlapping genes—including chemokines,
hemokine receptors, and cytokine-related genes, which con-
istently increased in both studies and at various stages of
therosclerotic lesion progression, and major histocompatibility
omplex molecules such as H2-Eb1 and H2-Ab1—associate
ith inflammation. Both studies identified increased levels of
ncostatin M receptor (Osmr) in atherosclerosis. Oncostatin M
Osm) belongs to a cytokine family that regulates endothelial
ell production of other cytokines, including interleukin-6,
ranulocyte colony-stimulating factor, and granulocyte macro-
hage colony-stimulating factor. Also Osm induces Abca1 in
epG2 cells (49) and Mmp3 and Timp3 gene expression via
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Atherosclerosis: Genomics to Therapeutics April 17, 2007:1589–99anus kinase/signal transducers and activators of transcription
ignaling (50). Both studies observed that increased levels of
smr, Jak3, and Abca1 associate with atherosclerosis progres-
ion. Both studies also detected increased levels of osteopontin
Spp1), a component of cell-mediated immunity (51), and a
ene intensively studied in relation to atherosclerosis.
Such unbiased transcriptional profiling approaches discov-
red genes such as Runx2, an Spp1-related transcript, previ-
usly not implicated in atherosclerosis. In addition, Tabibiazar
t al. (47) identified several other Spp1-related transcripts not
reviously associated with atherosclerosis. Both studies identi-
ed genes previously associated with atherosclerosis such as
cam1 and Timp1. Additionally, each study identified several
ther novel genes, and some appeared in both studies. For
xample, Tabibiazar et al. (47) and Karra et al. (46) both
etermined that the differential regulation of Xin, a gene
nvolved in cardiac and skeletal muscle development, associates
ith atherosclerosis and arterial repair, respectively. Both
tudies also determined that differential regulation of Sgcg, a
ene strongly expressed in skeletal and heart muscle as well as
roliferating myoblasts, associates with atherosclerosis.
Transcriptional profiling is especially advantageous in
enomic studies designed to detect an environmental stim-
lus. This extension of the concept to cell culture has
ermitted investigation of the influence of vascular dynam-
cs on transcripts related to atherosclerosis. Studying cul-
ured human vascular endothelial cells exposed to varying
hear stress, oxygen gradient, and oxidized LDL, Warabi
t al. (52) showed differential expression of several Nrf2-
elated genes in response to laminar flow, underscoring the
dvantage of precise environmental regulation in cell culture
ifferences in Gene Expression Associated With Atherosclerosis
Table 2 Differences in Gene Expression Associated With Ather
Class Symbol Gene
Inflammation Abca1 ATP-binding cassette subfamily A
Ccl9 Chemokine (C-C motif) ligand 9
CCr2 Chemokine (C-C motif) receptor
CCr5 Chemokine (C-C motif) receptor
Cklfsf7 Chemokine-like factor superfam
Cxcl1 Chemokine (C-X-C motif) ligand 1
Cxcr4 Chemokine (C-X-C motif) recepto
IL1rn Interleukin 1 receptor antagonist
IL7r Interleukin 7 receptor
H2-Eb1 Histocompatibility 2, class II anti
H2-Ab1 Response to metastatic cancers
Jak3 Janus kinase 3
Osmr Oncostatin M receptor
Runx2 Runt-related transcription factor
Adhesion Spp1 Secreted phosphoprotein 1
Timp1 Tissue inhibitor of metalloprotein
Vcam1 Vascular cell adhesion molecule
Development Sgcg Sarcoglycan, gamma
Xin/Cmya1 Cardiomyopathy associated 1
enes identified in 2 independent expression studies (46,47).
ATP  adenosine triphosphate.or transcriptional profiling. gDetection of transcripts in circulating cells offers conve-
ient clinical application of transcriptional profiling, but
ay not reflect gene expression in atherosclerotic lesions.
et one such strategy may nonetheless offer novel insight
nto the mechanisms of coronary thrombosis. Transcrip-
ional profiling of platelets from patients with acute coro-
ary syndromes offers the ability to examine gene transcrip-
ion that occurred in megakaryocytes some weeks before the
nset of symptoms. This approach has identified myeloid-
elated protein-14 as a novel marker of coronary risk (53).
How do transcriptional profiling experiments impact
ardiovascular therapeutics? Validated markers that emerge
rom gene expression profiling might improve risk stratifi-
ation and personalization of treatment decisions. Gene
xpression profiling may aid identification of drug targets
nd validation of candidate drugs for the management of
therosclerosis. As proof of principle, Tuomisto et al. (54)
howed that HMG-CoA reductase (the target of statin
rugs) increased in atherosclerotic plaque. Using laser cap-
ure microdissection to isolate macrophage-rich tissue from
uman atherosclerotic lesions, they compared expression
rofiles to normal intimal tissue and THP-1 macrophage-
ike cells and identified augmented expression of 72 genes
ncluding HMG-CoA reductase. Studying the transcrip-
ional effect of statin exposure on peripheral monocytes,
aehre et al. (55) provided evidence showing that statins
nhibit expression of inflammatory cytokine interleukin-1,
ormally present at high levels among subjects with CAD
55). Such findings show the potential of genomic tech-
iques to identify additional drug targets and provide
rosis
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April 17, 2007:1589–99 Atherosclerosis: Genomics to TherapeuticsIn another study based on expression profiling, CRP
ugmented the expression of matrix metalloproteinase
MMP)-1 and MMP-10 in human endothelial cell tran-
criptional profiling experiments (56). The MMPs are
articipants in plaque disruption and thrombosis. In another
tudy, purified CRP caused increased expression of genes
elated to programmed cell death such as GADD153 in
ultured vascular smooth muscle cells (57). Apoptosis of
ascular smooth muscle cells occurs in atheromata (58).
hus, expression profiling described a molecular link be-
ween inflammation and atherosclerotic lesions and pro-
ided a means for testing the effect of statins or other
ompounds on apoptosis-associated genes, pointing to novel
herapeutic approaches to atherosclerosis.
roteomic and Metabolomic
rofiling in Atherosclerosis
ven if replicated, association or transcriptional profiling
tudies cannot assess potentially important post-transcrip-
ional variables including alternative splicing of mRNA,
ontrol subjects on protein translation, and post-translational
rocessing of proteins (Fig. 2). Protein markers may provide
ore accurate real-time information about pathophysiology
han stable germ-line markers such as SNPs. As with
enomics, potential benefits to the clinical community
nclude better tools for diagnosis (cardiac biomarkers) and
dentification of therapeutic targets. The National Heart,
ung, and Blood Institute has supported this effort by
stablishing several Proteomics Centers (59), and several
ecent reports highlight progress and further challenges in
his area of cardiovascular research.
Challenges in the application of proteomics to cardiovas-
ular disease begin with the selection of tissue samples. For
xample, one study that sampled endarterectomy sections
ontaining atherosclerotic plaque determined decreased ex-
ression of heat shock protein-27 (HSP27) in plaque
ompared with healthy tissue, and confirmed these results
y showing a similar trend for the amount of soluble HSP27
n plasma of subjects with atherosclerotic cardiovascular
isease (60). Additionally, recent evidence suggests a pos-
ible connection between HSP27 and atherosclerosis at the
evel of estrogen signaling (61). Others have pointed to
onfounding in studies of atherosclerotic plaque because of
he heterogeneity of cell types (62). Yet breaking down the
omponents of a plaque without inducing experimental
rtifact also presents challenges. Although circulating
lasma may not reflect all aspects of an atherosclerotic
esion, it offers accessibility and reproducibility of sample
ollection. Given the overwhelming abundance of certain
roteins such as albumin in blood, ferreting out changes in
evels of much less abundant proteins such as cytokines and
rowth factors presents a formidable technical challenge.
As in the case of genomic markers, proteomic studies
equire rigorous validation of technology platforms and
xperimental results. Providing a foundation for study fnterpretation, the Human Proteome Organization initiated
Plasma Proteome Project. The pilot phase identified 345
ardiovascular disease-related proteins in human plasma
63,64). These catalogs determine additional novel proteins
hat might associate with cardiovascular disease in future
roteomic discovery experiments. Such databases accelerate
he identification of unknown markers present in athero-
clerotic cardiovascular disease.
Proteomic studies on isolated plasma lipid fractions have
ielded new insight into the composition of LDL and
igh-density lipoprotein particles, identifying 3 proteins
reviously not associated with LDL and 2 proteins not
reviously associated with high-density lipoprotein (65,66).
avidsson et al. (67) described unique patterns of LDL-
ssociated apolipoproteins in subjects with type 2 diabetes
nd subclinical peripheral atherosclerosis compared with
ealthy control subjects, suggesting that particular distribu-
ions of LDL-associated apolipoproteins in subjects with
ype 2 diabetes could contribute to the increased incidence
f atherosclerotic cardiovascular disease in that group.
Metabolomics seeks to quantify small molecules that
erve as physiological indicators within circulating plasma or
articular cells and tissues. The potential list of small
olecules runs into the thousands and includes carbohy-
rates, peptides, lipids, and metabolic intermediates such as
mino acids, organic acids, and drug metabolites. Quanti-
cation is generally based on various methods of spectros-
opy or chromatography, techniques that could provide
apid high-throughput results at relatively low cost in
linical practice. Noninvasive sampling of plasma to identify
eal-time markers of CAD has been reported (68), but clinical
pplications of this technology must first overcome technolog-
cal and statistical limitations in simultaneously detecting
yriad compounds across a broad concentration range.
As proof of principle, Sabatine et al. (69) used mass
pectrometry-based technology to identify differences in
lasma metabolites among 18 subjects with ischemia in-
uced by exercise stress testing compared with nonischemic
ndividuals who also exercised; specifically, changes in 6
etabolites, including citric acid, accurately differentiated
ases from control subjects (p  0.0001). Although requir-
ng further study, combining small molecule profiling with
he arsenal of genomic and proteomic technologies should
rovide additional diagnostic information and improve our
bility to identify new therapeutic targets. Identifying rele-
ant proteomic and metabolomic markers will benefit from
omparison with genetic and genomic data. Future experi-
ents should compare fluctuations of cardiovascular bio-
arkers with other epidemiologic factors such as age,
ender, ethnicity, and a variety of environmental exposures
lready recognized to influence disease risk and outcome.
cientific Community Genomic Resources
enetic and genomic studies of atherosclerosis are moving
orward rapidly thanks to sharing of resources such as the
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Atherosclerosis: Genomics to Therapeutics April 17, 2007:1589–99uman Genome Project and The International HapMap
i.e., haplotype map) Project. HapMap recently completed
ystematic genotyping of 3 million SNPs in each of 269
ubjects representing 4 different ethnic groups, offering
igh-resolution information about inheritance patterns of
ommon SNP alleles throughout the genome (70). Such
nformation facilitates development of high-throughput
enotyping technologies allowing researchers to perform
enome-wide association studies at ever lower costs per
ample. Detailed genotype information in HapMap facili-
ates fine mapping of areas identified in linkage studies and
rovides a valuable community resource for patterns of
enetic variation in diverse ethnic groups, thus simplifying
he statistical analysis of genetic association studies. Com-
unity efforts such as the MicroArray Quality Control
roject aim to improve reliability and validity of gene
xpression data (71), and the same will be necessary for
roteomics and metabolomics.
enomic Data Integration
ntegrating various forms of genomic data, so-called
enomic convergence, would yield a whole greater than the
um of its parts. Overlapping signals from linkage analysis,
ssociation studies, and expression profiling would facilitate
dentification of relevant markers. Identifying markers
hrough multiple experimental approaches reduces bias and
trengthens validity. Such nonbiased approaches are of
articular interest in the discovery of genomic markers that
mpact complex traits, such as atherosclerosis. More impor-
antly to clinical translation, cross-referencing with pro-
eomic and metabolomic profiles could identify markers
ore easily measured in a clinical setting.
Comparisons of such large data sets are biased toward
alse-positive results. Statistical methods for meeting this
hallenge are manifold and reviewed elsewhere (72,73). In
eneral terms, approaches to large genomic data sets include
ata normalization, filtering, and correction algorithms for the
umerous significant p values generated by thousands of
omparisons. At best, these measures will help refine the list of
rime candidates for further replication. Identifying clinically
pplicable genomic, proteomic, and metabolomic markers
equires consistent replication across populations, a challenge
est addressed through collaborative research efforts.
linical Applications of
enomics to Cardiovascular Medicine
enomic-based cardiovascular risk prediction models.
ardiovascular genomic, proteomic, and metabolomic re-
earch will continue to identify molecular markers—
enotypes, RNA expression levels, proteomic and
etabolomic markers—associated with cardiovascular dis-
ase, thus revealing new therapeutic targets. In atheroscle-
osis, many factors influence disease predisposition and
herapeutic response, providing an appropriate testing
round for a personalized medicine approach based on oonvergence of information. Future risk assessment models
ill likely incorporate a patient’s genomic, proteomic,
etabolomic, and environmental information, using statis-
ical models to identify marker-disease associations and
orrect for confounders such as gene-environment interac-
ions (i.e., patients with a particular marker will have high
isk only if exposed to a particular stimulus). Avoidance of
hat stimulus offers a more tractable intervention for both
atient and physician.
Data networks that combine various forms of information
ill greatly assist this process by identifying, for example,
etabolomic markers that vary in response to a patient’s
enetic makeup and environmental exposures. Decision algo-
ithms will harness information generated by medical and
amily histories, clinical criteria such as the Framingham Score,
nd multiple genetic, genomic, and biomarker tests (Fig. 3).
linicians might wonder why we are not yet testing patients
or genetic markers such as ALOX5AP or TNFSF4 SNPs.
uite simply, our current knowledge of the risk attributable to
hese variants is applicable only to a population, not to
ndividuals. Providing patient-specific risk information based
Figure 3 Coordination of Information
for Clinical Decision-Making
Informed clinical decision-making based on genomic information will require
synthesis of diverse pieces of data. The relative significance of genomic, pro-
teomic, and metabolomic markers could vary among patients. Such information
must be considered in the context of personal medical history, family history,
other clinical and laboratory data, and environmental variables. ECG  electro-
cardiography. Illustration by Rob Flewell.n genomic markers awaits a more comprehensive understand-
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April 17, 2007:1589–99 Atherosclerosis: Genomics to Therapeuticsng of how these variants interact with each patient’s genetic
ackground and other risk factors.
enomics for Identifying Therapeutic Targets
ewer genome-wide approaches may uncover additional
ovel markers of disease risk that represent new drug
argets. The human genome likely contains more than
2,000 genes (see the preceding text), of which current
edications target only 500 (74). Genomic approaches
an identify novel drug targets. Unfortunately, the path
rom potential target discovery to development of useful
herapeutics presents considerable challenges. Microarray
xperiments might identify multiple potential targets, but
rioritization of that list presents a challenge. Given a list of
00 or 1,000 candidate genes, researchers likely will focus on
he ones they recognize; however, this bias could overlook
iable targets.
However, progress in CAD gene identification drives
evelopment of potential therapeutics. For example, treat-
ent of 191 subjects who carried at-risk variants in the
LOX5AP or LTA4H genes with a FLAP inhibitor reduced
evels of LTB4, a biomarker associated with MI risk (75),
CSK9 inhibitors seem a ripe target for adjunct therapy in
atients in whom LDL targets are not achieved on statins
ither as monotherapy or combined with cholesterol absorp-
ion inhibitors, or who cannot tolerate high-dose statins.
oreover, studies of LTA4H and PCSK9 among African
mericans may increase our understanding of ethnicity’s
ontribution to CAD.
ummary for Clinicians
apid advances in genomic, proteomic, and metabolomic
echnology provide researchers with valuable tools for un-
erstanding the genetic predisposition to atherosclerotic
ardiovascular disease. Genetic, proteomic, and metabolo-
ic markers will add diagnostic accuracy and perhaps
redict the onset and severity of atherosclerotic cardiovas-
ular disease. Early results from genetic association studies
nd genomic profiling of gene expression provide proof of
oncept for consistent and reproducibly associated predis-
osition of genomic markers to cardiovascular disease.
Clinical translation will require validation in prospective
tudies that encompass large, ethnically diverse cohorts.
ombining classical epidemiology with modern genomics
ill yield unprecedented insight into mechanisms of disease,
nd also will generate ever more risk markers. Performing
ests on patients is relatively easy. Despite test sophistica-
ion, high-throughput automation will allow clinical labo-
atories to offer testing at costs similar to most diagnostic
maging studies. Interpreting such test results will truly
rovide a challenge. Indeed, prospective validation of new
isk markers likely will limit the rate of progress more than
ny technical or experimental factors.
Genetic, genomic, proteomic, and metabolomic tests will
dd to rather than replace the clinical utility of traditional
1ardiovascular risk markers. Elements of the Framingham
core will remain relevant. However, newer information
ill temper and refine the relative importance of traditional
arkers. Framingham Scores do not include family history
ata, leaving room to incorporate genetic and genomic
nformation into the screening process. Because DNA-
ased genetic markers remain static throughout life, predic-
ive genetic tests could be performed at very young ages to
acilitate early intervention. On the other hand, gene ex-
ression profiling and serum biomarkers provide real-time
nformation that integrates current environmental influ-
nces, and likely aid diagnostic categorization and the early
etection of disease. Again, a coordinated screening ap-
roach that maximizes the benefits of each screening mo-
ality will provide the most clinical utility.
Finally, genomic approaches have already identified po-
ential drug targets. Inhibitors of FLAP, OX40L-OX40
inding, MMP, and PCSK9 are all attractive candidates for
AD risk modifiers. Although inherent challenges of
ringing any new drug to the clinic will influence the pace
f introduction of therapeutic changes, genomic approaches
o cardiology promise to bring lasting improvements to
atient care. Clinical translation of genomic, proteomic, and
etabolomic information will require collaborative efforts
ithin the cardiovascular disease community at both bench
nd bedside.
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